

IN THE CLAIMS

1-13. (cancelled)

14. (original) A method for increasing T cell diversity in a subject in need thereof, said method comprising administering polyclonal immunoglobulin to said subject and monitoring T cell diversity in said subject.

15. (original) The method of claim 14, wherein said subject has an autoimmune disease.

16. (original) The method of claim 15, wherein said autoimmune disease is selected from the group consisting of rheumatoid arthritis, insulin-dependent diabetes mellitus, myasthenia gravis, systemic lupus erythematosus, and inflammatory bowel disease.

17. (original) The method of claim 14, wherein said subject has AIDS.

18. (original) The method of claim 14, wherein said subject has a congenital immunodeficiency.

19. (original) The method of claim 18, wherein said subject has severe combined immunodeficiency, common variable immunodeficiency, DiGeorge syndrome, or hyper IgM syndrome.

20. (original) The method of claim 14, wherein said subject has cancer.

21. (original) The method of claim 14, wherein said subject has a chronic infection.

22. (original) The method of claim 14, wherein said subject has undergone partial or complete thymectomy.

23. (original) The method of claim 14, wherein said subject is at least 20 years old.

24. (original) The method of claim 14, wherein said polyclonal immunoglobulins are Fab fragments.
25. (original) The method of claim 14, wherein said polyclonal immunoglobulins are reduced monomers.
26. (original) The method of claim 14, wherein said polyclonal immunoglobulin is recombinant.
27. (original) The method of claim 14, wherein T cell diversity is monitored using a population of random or diverse nucleic acid molecules.
28. (original) A method for enhancing T cell diversity in a thymectomized subject, said method comprising administering polyclonal immunoglobulin to said subject.
- 29-32. (cancelled)